MA56553A - Tétrahydropyranyl-amino-pyrrolopyrimidinone pour une utilisation dans un procédé de traitement d'un trouble médié par btk - Google Patents
Tétrahydropyranyl-amino-pyrrolopyrimidinone pour une utilisation dans un procédé de traitement d'un trouble médié par btkInfo
- Publication number
- MA56553A MA56553A MA056553A MA56553A MA56553A MA 56553 A MA56553 A MA 56553A MA 056553 A MA056553 A MA 056553A MA 56553 A MA56553 A MA 56553A MA 56553 A MA56553 A MA 56553A
- Authority
- MA
- Morocco
- Prior art keywords
- pyrrolopyrimidinone
- btk
- tetrahydropyranyl
- amino
- treating
- Prior art date
Links
- QBCYEGVJTIOUCK-UHFFFAOYSA-N 4-amino-6-(oxan-2-yl)pyrrolo[3,2-d]pyrimidin-2-one Chemical compound O1C(CCCC1)C1=CC=2C(C(=NC(N=2)=O)N)=N1 QBCYEGVJTIOUCK-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2015/000285 WO2017111787A1 (fr) | 2015-12-23 | 2015-12-23 | Tétrahydropyranyl-amino-pyrrolopyrimidinone et procédés d'utilisation associés |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA56553A true MA56553A (fr) | 2022-04-27 |
| MA56553B1 MA56553B1 (fr) | 2023-04-28 |
Family
ID=59090991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA56553A MA56553B1 (fr) | 2015-12-23 | 2015-12-23 | Tétrahydropyranyl-amino-pyrrolopyrimidinone pour une utilisation dans un procédé de traitement d'un trouble médié par btk |
Country Status (28)
| Country | Link |
|---|---|
| EP (2) | EP3882250B1 (fr) |
| JP (1) | JP6634520B2 (fr) |
| KR (2) | KR102746900B1 (fr) |
| CN (2) | CN108699062B (fr) |
| AU (3) | AU2015417922B2 (fr) |
| CA (1) | CA3008446C (fr) |
| CY (1) | CY1124210T1 (fr) |
| DK (2) | DK3882250T3 (fr) |
| ES (2) | ES2942743T3 (fr) |
| FI (1) | FI3882250T3 (fr) |
| HR (2) | HRP20210844T1 (fr) |
| HU (2) | HUE061761T2 (fr) |
| IL (2) | IL259938B (fr) |
| LT (2) | LT3882250T (fr) |
| MA (1) | MA56553B1 (fr) |
| MD (1) | MD3882250T2 (fr) |
| MX (1) | MX384022B (fr) |
| MY (1) | MY193177A (fr) |
| PH (1) | PH12018501390B1 (fr) |
| PL (2) | PL3882250T3 (fr) |
| PT (2) | PT3394065T (fr) |
| RS (2) | RS64141B1 (fr) |
| RU (1) | RU2715421C2 (fr) |
| SA (1) | SA518391836B1 (fr) |
| SG (1) | SG11201805154YA (fr) |
| SI (2) | SI3882250T1 (fr) |
| WO (1) | WO2017111787A1 (fr) |
| ZA (1) | ZA201804091B (fr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201901197PA (en) * | 2016-08-24 | 2019-03-28 | Arqule Inc | Amino-pyrrolopyrimidinone compounds and methods of use thereof |
| CN109956870A (zh) * | 2017-12-14 | 2019-07-02 | 南京卡文迪许生物工程技术有限公司 | 一种罗沙司他的合成方法及其中间体化合物 |
| BR112021023607A2 (pt) * | 2019-05-31 | 2022-01-04 | Fochon Pharmaceuticals Ltd | Derivados de pirrolo[2,3-b]piridina e pirazolo[3,4-b]piridina substituídos por inibidores de proteína quinase |
| CN114728974B (zh) * | 2019-11-13 | 2023-09-19 | 浙江龙传生物医药科技有限公司 | 作为btk抑制剂的吡咯并嘧啶类化合物及其应用 |
| CN112812100B (zh) * | 2019-11-18 | 2022-04-05 | 四川海思科制药有限公司 | 一种具有降解btk激酶的化合物及其制备方法和药学上的应用 |
| CN112608318B (zh) * | 2019-12-16 | 2023-09-08 | 成都海博为药业有限公司 | 一种作为蛋白质激酶抑制剂的化合物及其用途 |
| JP7011638B2 (ja) * | 2019-12-16 | 2022-02-10 | アークル インコーポレイテッド | テトラヒドロピラニルアミノ－ピロロピリミジノンおよびその使用の方法 |
| US20230122807A1 (en) * | 2020-01-02 | 2023-04-20 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Btk inhibitors |
| WO2022105746A1 (fr) * | 2020-11-17 | 2022-05-27 | Fochon Pharmaceuticals, Ltd. | Dérivés de pyrrolo[2,3-b]pyridine et de pyrazolo[3,4-b]pyridine substitués en tant qu'inhibiteurs de protéine kinase |
| CN112574200B (zh) * | 2021-02-26 | 2021-06-11 | 安润医药科技（苏州）有限公司 | Btk和/或btk的突变体c481s的小分子抑制剂 |
| CN115028633B (zh) * | 2021-03-08 | 2023-12-22 | 药雅科技(上海)有限公司 | 吡咯并嘧啶类化合物的制备及其应用 |
| CN114761410B (zh) * | 2021-04-06 | 2023-08-25 | 广州必贝特医药股份有限公司 | 吡咯并嘧啶酮类化合物及其应用 |
| WO2022213932A1 (fr) * | 2021-04-06 | 2022-10-13 | 广州必贝特医药股份有限公司 | Composé de pyrrolopyrimidinone et son utilisation |
| JP7645573B2 (ja) * | 2021-05-12 | 2025-03-14 | ジャージアン・ロングチャーム・バイオ－テック・ファーマ・カンパニー・リミテッド | ピロロピリミジン類化合物の結晶形およびその調製方法 |
| US20250074911A1 (en) | 2021-12-14 | 2025-03-06 | Crossfire Oncology Holding B.V. | Macrocyclic btk inhibitors |
| CN114409654A (zh) * | 2021-12-30 | 2022-04-29 | 安徽普利药业有限公司 | 一种btk抑制剂的中间体合成方法 |
| CN115894500B (zh) * | 2022-11-02 | 2024-05-28 | 中国药科大学 | 一种作为btk激酶抑制剂的化合物及其制备方法与用途 |
| CN118702697A (zh) * | 2023-03-18 | 2024-09-27 | 山东新时代药业有限公司 | 苯甲酰基吡咯并嘧啶类衍生物及其用途和制备方法 |
| CN116375715B (zh) * | 2023-04-06 | 2025-04-04 | 中国药科大学 | 一种作为非共价btk激酶抑制剂的化合物及其生物用途 |
| WO2024245578A1 (fr) | 2023-06-02 | 2024-12-05 | Netherlands Translational Research Center Holding B.V. | Combinaisons thérapeutiques d'un inhibiteur de btk irréversible et d'un inhibiteur de btk réversible macrocyclique |
| WO2024245577A1 (fr) | 2023-06-02 | 2024-12-05 | Netherlands Translational Research Center Holding B.V. | Combinaisons thérapeutiques d'un inhibiteur irréversible de btk et d'un inhibiteur réversible de btk |
| WO2024246287A1 (fr) | 2023-06-02 | 2024-12-05 | Crossfire Oncology Holding B.V. | Utilisation médicale d'un inhibiteur de btk réversible macrocyclique |
| WO2024256568A1 (fr) | 2023-06-13 | 2024-12-19 | Crossfire Oncology Holding B.V. | Formes salines et formes cristallines d'un inhibiteur de btk macrocyclique |
| WO2024256574A1 (fr) | 2023-06-13 | 2024-12-19 | Crossfire Oncology Holding B.V. | Procédé de préparation d'inhibiteurs de btk macrocycliques |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| KR20120097512A (ko) * | 2009-11-18 | 2012-09-04 | 플렉시콘, 인코퍼레이티드 | 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증 |
| US8377946B1 (en) * | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| US9012466B2 (en) * | 2013-03-12 | 2015-04-21 | Arqule Inc. | Substituted tricyclic pyrazolo-pyrimidine compounds |
| US8940893B2 (en) * | 2013-03-15 | 2015-01-27 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as BTK inhibitors |
| GB201309085D0 (en) * | 2013-05-20 | 2013-07-03 | Redx Pharma Ltd | Compounds |
| GB201410430D0 (en) * | 2014-06-11 | 2014-07-23 | Redx Pharma Ltd | Compounds |
-
2015
- 2015-12-23 FI FIEP21165852.1T patent/FI3882250T3/fi active
- 2015-12-23 PT PT159114909T patent/PT3394065T/pt unknown
- 2015-12-23 CN CN201580085832.0A patent/CN108699062B/zh active Active
- 2015-12-23 WO PCT/US2015/000285 patent/WO2017111787A1/fr not_active Ceased
- 2015-12-23 RS RS20230294A patent/RS64141B1/sr unknown
- 2015-12-23 DK DK21165852.1T patent/DK3882250T3/da active
- 2015-12-23 ES ES21165852T patent/ES2942743T3/es active Active
- 2015-12-23 RS RS20210646A patent/RS61887B1/sr unknown
- 2015-12-23 SG SG11201805154YA patent/SG11201805154YA/en unknown
- 2015-12-23 KR KR1020237020794A patent/KR102746900B1/ko active Active
- 2015-12-23 KR KR1020187020899A patent/KR102547188B1/ko active Active
- 2015-12-23 PH PH1/2018/501390A patent/PH12018501390B1/en unknown
- 2015-12-23 MX MX2018007815A patent/MX384022B/es unknown
- 2015-12-23 MY MYPI2018001066A patent/MY193177A/en unknown
- 2015-12-23 HR HRP20210844TT patent/HRP20210844T1/hr unknown
- 2015-12-23 CN CN202110663289.5A patent/CN113307811B/zh active Active
- 2015-12-23 PL PL21165852.1T patent/PL3882250T3/pl unknown
- 2015-12-23 SI SI201531934T patent/SI3882250T1/sl unknown
- 2015-12-23 RU RU2018126793A patent/RU2715421C2/ru active
- 2015-12-23 JP JP2018533095A patent/JP6634520B2/ja active Active
- 2015-12-23 MA MA56553A patent/MA56553B1/fr unknown
- 2015-12-23 HR HRP20230379TT patent/HRP20230379T1/hr unknown
- 2015-12-23 ES ES15911490T patent/ES2868884T3/es active Active
- 2015-12-23 LT LTEP21165852.1T patent/LT3882250T/lt unknown
- 2015-12-23 HU HUE21165852A patent/HUE061761T2/hu unknown
- 2015-12-23 EP EP21165852.1A patent/EP3882250B1/fr active Active
- 2015-12-23 LT LTEP15911490.9T patent/LT3394065T/lt unknown
- 2015-12-23 EP EP15911490.9A patent/EP3394065B1/fr active Active
- 2015-12-23 CA CA3008446A patent/CA3008446C/fr active Active
- 2015-12-23 PT PT211658521T patent/PT3882250T/pt unknown
- 2015-12-23 AU AU2015417922A patent/AU2015417922B2/en active Active
- 2015-12-23 MD MDE20220501T patent/MD3882250T2/ro unknown
- 2015-12-23 DK DK15911490.9T patent/DK3394065T3/da active
- 2015-12-23 HU HUE15911490A patent/HUE055221T2/hu unknown
- 2015-12-23 PL PL15911490T patent/PL3394065T3/pl unknown
- 2015-12-23 SI SI201531588T patent/SI3394065T1/sl unknown
-
2018
- 2018-06-11 IL IL259938A patent/IL259938B/en active IP Right Grant
- 2018-06-19 ZA ZA2018/04091A patent/ZA201804091B/en unknown
- 2018-06-20 SA SA518391836A patent/SA518391836B1/ar unknown
-
2019
- 2019-03-13 AU AU2019201737A patent/AU2019201737B2/en active Active
-
2020
- 2020-06-04 AU AU2020203690A patent/AU2020203690B2/en active Active
-
2021
- 2021-04-22 IL IL282572A patent/IL282572B/en unknown
- 2021-05-31 CY CY20211100469T patent/CY1124210T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA56553A (fr) | Tétrahydropyranyl-amino-pyrrolopyrimidinone pour une utilisation dans un procédé de traitement d'un trouble médié par btk | |
| EP3443013A4 (fr) | Procédés d'utilisation de l'expression de pd-l1 dans des décisions de traitement pour la thérapie anticancéreuse | |
| EP3374502A4 (fr) | Procédés pour le traitement de dystrophies cornéennes | |
| EP3324965A4 (fr) | Modulateurs de la gamma-sécrétase pour le traitement de dysfonctionnement du système immunitaire | |
| EP3386655C0 (fr) | Procédé pour le traitement de déchets | |
| EP3454535A4 (fr) | Procédé et dispositif pour une interaction dans un appel | |
| FR3050672B1 (fr) | Automate pour le traitement d'une surface | |
| EP3395354A4 (fr) | Procédé pour empêcher et traiter une néphropathie diabétique | |
| MA41555A (fr) | Polythérapie pour le traitement du cancer | |
| EP2961559A4 (fr) | Système laser et procédé pour le traitement du saphir | |
| MA42999A (fr) | Polythérapie pour le traitement de malignités | |
| MA46079A (fr) | Procédé pour apporter un bénéfice à la peau | |
| EP3412259A4 (fr) | Source lumineuse pour article réduisant la myopie et procédé d'utilisation d'une source lumineuse pour article réduisant la myopie | |
| EP3503890A4 (fr) | Utilisation de la pridopidine pour le traitement des dystonies | |
| MA45429A (fr) | Polythérapie pour le traitement du cancer | |
| EP3349908A4 (fr) | Dispositif et procédé pour enlever une matière indésirable | |
| EP3314062A4 (fr) | Système de pièce d'usure et procédé pour verrouiller une pièce d'usure | |
| MA41123A (fr) | Polythérapie pour le traitement du cancer | |
| EP3277861A4 (fr) | Procédé de traitement de solution d'électrolyte liquide | |
| EP3334432A4 (fr) | Cerdulatinib pour le traitement du myélome | |
| EP3122957A4 (fr) | Écrou et procédé pour fixer un objet à une structure de construction | |
| EP3337315A4 (fr) | Procédé et agencement pour vider une cage d'élevage d'organismes marins | |
| EP3523932A4 (fr) | Procédé et appareil pour filtrer une pluralité de messages | |
| EP3464197A4 (fr) | Élimination de métaux lourds dans un traitement lesté | |
| EP3525147A4 (fr) | Procédé et dispositif de partage de message dans une région |